WO2024073011A1 - Compositions topiques et procédés pour le traitement de maladies fibrotiques dermiques et transdermiques, de troubles et de la douleur et de l'inflammation associées - Google Patents

Compositions topiques et procédés pour le traitement de maladies fibrotiques dermiques et transdermiques, de troubles et de la douleur et de l'inflammation associées Download PDF

Info

Publication number
WO2024073011A1
WO2024073011A1 PCT/US2023/034056 US2023034056W WO2024073011A1 WO 2024073011 A1 WO2024073011 A1 WO 2024073011A1 US 2023034056 W US2023034056 W US 2023034056W WO 2024073011 A1 WO2024073011 A1 WO 2024073011A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
acid
composition
vitamin
disease
Prior art date
Application number
PCT/US2023/034056
Other languages
English (en)
Inventor
David Scharp
Mukhtar Siddiqui
Jennifer HURTIKANT
David Bondurant
Brian HAIGHT
Kai Hansen
David J. Austin
Original Assignee
Eresina, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eresina, Llc filed Critical Eresina, Llc
Publication of WO2024073011A1 publication Critical patent/WO2024073011A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • compositions and methods of the present disclosure relate generally to the field of treatments for fibrotic diseases, disorders and associated pain and inflammation, and methods of manufacture thereof.
  • the application further discloses compositions for treatment of topical orphan diseases and related syndromes, and methods of treatment and process of manufacture of disclosed compositions.
  • fibrotic diseases and disorders include but are not limited to Dupuytren’s disease (palmar fascia fibromatosis), Dupuytren’s contracture, Ledderhose’s disease, Peyronie’s disease, scleroderma, and Raynaud’s (or Renaud’s) phenomenon, wound healing, such as skin damage from cuts, abrasions and bums, as well as aging skin changes, toe nail fungus, and chemotherapy and/or radiation induced oral mucosal ulceration and aphthous ulcers.
  • Dupuytren’s disease palmar fascia fibromatosis
  • Dupuytren’s contracture Ledderhose’s disease
  • Peyronie’s disease scleroderma
  • Raynaud’s or Renaud’s
  • Orphan diseases include several well-known diseases, like cystic fibrosis and Tourette's syndrome, but most are unknown to the general public.
  • the orphan diseases of interest in this application are Dupuytren's Contracture, Peyronie's Disease, Scleroderma, Raynaud's (or Renaud's) Phenomenon, Chemotherapy / Radiation Induced Oral Mucosal Ulceration, and Aphthous Ulcers; and more frequent skin issues of Skin Damage from Cuts, Abrasions, and Bums; Aging Skin Changes, and Toe Nail Fungus.
  • the diseases and disorders of the present invention include diseases and disorders having a fibrotic component.
  • Fibrosis is a pathogenic hallmark of a vast number of conditions, implicating a wide variety of tissues, including joints and interstitial tissues (e.g., arthrofibrosis, Dupuytren's disease), the skin (e.g., keloid lesions, nephrogenic systemic fibrosis, scleroderma), the mouth (e.g., fibrous proliferative lesions of the oral cavity), the vasculature, including the peripheral vasculature, among others.
  • interstitial tissues e.g., arthrofibrosis, Dupuytren's disease
  • the skin e.g., keloid lesions, nephrogenic systemic fibrosis, scleroderma
  • the mouth e.g., fibrous proliferative lesions of the oral cavity
  • the vasculature including the peripheral vasculature, among others.
  • Fibrosis may result from environmental insults or injury, such as, for example, exposure to ionizing radiation (such as during cancer treatments), as a result of cystic rupture in the breast, (causing palpable lesions in mammary tissue), and generally as a result of overdeposition of collagen following a wound or tissue insult, such as after injury or surgery.
  • environmental insults or injury such as, for example, exposure to ionizing radiation (such as during cancer treatments), as a result of cystic rupture in the breast, (causing palpable lesions in mammary tissue), and generally as a result of overdeposition of collagen following a wound or tissue insult, such as after injury or surgery.
  • fibrosis While some types of fibrosis involve underlying genetic predispositions e.g., Dupuytren’s disease), many types of fibrosis involve prolonged inflammation of the affected tissue. Symptoms may be as minor as pruritis and aesthetic concerns, such as keloid lesions of the skin, or as significant as pulmonary failure and death, for example in terminal symptoms of pulmonary fibroses and cardiac fibroses.
  • Current antifibrotic treatments include anti-inflammatory compounds such as pirfenidone and fibroblast growth factor receptor antagonist nintedanib.
  • therapies are largely limited to surgery, phototherapy and/or injections at the site of fibrosis. Due to the invasiveness and limited efficacy of current therapies, there remains a need for additional therapeutic approaches to this class of conditions.
  • Inflammation is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators.
  • the function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and initiate tissue repair. Inflammation can be classified as either acute or chronic.
  • Acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes from the blood into the injured tissues.
  • a series of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue.
  • Prolonged inflammation known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation, such as mononuclear cells, and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process, which often leads to a host of diseases including fibroses.
  • Dupuytren’s disease (also known as (palmar fascia fibromatosis) is a disease associated with the buildup of extracellular matrix materials such as collagen in the connective tissue characterized by thickening of the palmar fascia of the hand. The connective tissue thickens and shortens with the physical effect of causing the fingers to curl, most commonly the ring finger and little finger.
  • Dupuytren’s disease is a complex fibrosis proliferative disorder of the hand that is often progressive and eventually can cause contractures of the affected fingers. Contracture is referred to as Dupuytren’s contracture and is an advanced stage of the disorder that is particularly difficult to treat.
  • Dupuytren’s disease is characterized by thickening and contracture of the fascia (connective tissue) of the palm, usually progressing to flexion deformities and involvement of one or more fingers. This results from formation of longitudinal cords of indurated fibrous tissue in the palm and extending into the finger. A similar lesion sometimes occurs in the foot, known as Ledderhose’s disease.
  • Dupuytren’s disease affects approximately 5% of the white Caucasian population. The most common manifestation is progressive flexion contracture of the fingers, resulting in significantly compromised function. The causes of Dupuytren’s disease are not well understood and underlying disease is not currently curable.
  • Dupuytren Contracture is one of the diseases with few people but who suffer great pain and difficulty with life. About 15 million Americans age 35 and older have Dupuytren disease, which is about 5% of the US population. 3 million in the US have bent fingers from Dupuytren disease and 750,000 Americans have severe Dupuytren biology and the risk of being crippled even with available treatment. After age 55, the percent of people with Dupuytren disease increases steadily in both men and women. By age 70, one-quarter of men have signs of Dupuytren, increasing to one-third by age 80. Dupuytren is more common in women than men in those 85 and older. The total number of US Dupuytren cases increased from 14.2 million in 2000 to 16.2 million people in 2010. The percent of the US population 35 and older affected with Dupuytren disease increased from 8.7% in 2000 to 9.3% in 2010.
  • Dupuytren's Contracture is a rare connective tissue disorder characterized by fixation of the joints of certain fingers in a permanently flexed position. Due to abnormal thickening and shortening of the bands of fibrous tissue beneath the skin of the palm, a hardened nodule may develop, eventually forming an abnormal band of hardened fibrotic tissue. This causes the fingers of the affected area to begin to be drawn in toward the palm over several months or years and cannot be pulled back. The skin of the affected area may pucker. The ring and pinky fingers are most affected and usually both hands are affected.
  • Myofibroblast cells are known to be involved in both natural fibrosis and fibrotic disorders throughout the human body. (See, e.g., Hinz B, Lagares D. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol. 2020 Jan; 16(1): 11-31.) Inhibition of myofibroblasts has been reported to be a viable therapeutic target for the treatment and potential reversal of fibrosis disorders. (Id. at pg. 23, right column, lines 15- 17.)
  • the present invention involves, in part, mitigation of myofibroblasts through inhibition of crucial myofibroblast signalling pathways and cytotoxicity.
  • the present invention further involves mitigation of the inflammation associated with fibrosis and fibrotic disorders by mitigating the inflammatory response, including inhibition of crucial inflammatory cell signalling pathways and cytotoxicity, for example macrophages.
  • Treatment of Dupuytren’s disease and contracture has traditionally involved surgical excision of the offending tissue.
  • the surgical excision may be combined with excision of the overlying palmar skin and resurfacing of the cutaneous defect with full thickness skin graft.
  • Surgery is typically followed by prolonged rehabilitation, usually lasting 3 months and complications have been reported in up to 20% of cases.
  • Such surgical correction is the mainstay treatment of later stage Dupuytren’s contracture where secondary changes to tendons and joints have developed.
  • a less invasive surgical intervention is needle aponeurectomy in which the fibrous bands (contractures) in connective tissue are divided using the bevel of a needle.
  • Enzymatic cleavage of the affected tissue has been the focus of development to reduce invasiveness associated with surgery and improve recovery time of surgical treatment.
  • Clostridial collagenase a bacterial collagenase
  • U.S. Pat. No. RE39,941 U.S. Pat. No. 5,589, 171 and U.S. Pat. No. 6,086,872 describe the use of bacterial collagenase for the enzymatic cleavage of connective tissue in the treatment of Dupuytren's disease.
  • Xiaflex® is associated with high cost, possible allergic reactions, and development of neutralizing antibodies.
  • Bacterial collagenase therapy has been associated with improved outcomes in the treatment of Dupuytren’s disease when injected into the affected areas of contractures, but it is expensive and is associated with development of neutralizing antibodies.
  • Peyronie’s disease is a connective tissue disorder of the penis that may be likened to Dupuytren’s contracture of the hand. It is characterized by the triad of bent erections, pain in the penis with erections and palpable penile plaque. Peyronie’s disease is quite common, affecting as many as one in 11 men, despite the lack of public awareness.
  • the penis is composed of the same connective tissue as every other joint in the body.
  • the anatomy of the penis is composed of three cylinders: the paired erectile bodies and the urethra.
  • the erectile bodies are made up of sinusoidal tissue that fills up with blood during an erection and an outer covering (tunica albuginea) composed of tough fibroelastic tissue.
  • the outer covering determines the size and shape of the erection.
  • the principal finding in men with Peyronie’s disease is the deposition of scar tissue in the tunica albuginea. All of the clinical symptoms are derived from this event. The curvature of the penis is due to the fact that scar tissue does not stretch as well as normal tissue.
  • the normal tunica albuginea is composed of elastin fibers and collagen.
  • the site of scar tissue from Peyronie’s disease is composed mostly of collagen that may harden to the thickness of bone.
  • the palpable plaque is the actual scar tissue that has been deposited on the outer covering of the erectile bodies. This is present in the vast majority — but not all — patients with Peyronie’s disease. The plaque may become calcified, like bone, with severe disease. The pain experienced with erections in men suffering from Peyronie’s disease is believed to be due to active inflammation in the plaque.
  • Peyronie’s disease is induced by trauma.
  • the trauma may be acute and distinct such as a penile fracture, but more often it is chronic and low grade, such as repeated attempts at sexual intercourse with weak or incomplete erections.
  • Peyronie’s disease is similar to Dupuytren's Contracture as both involve a connective tissue disorder.
  • Peyronie’s disease is characterized by the development of fibrous plaques in the soft tissue of the penis of adult males which results in penile deformity. It is estimated to affect 0.5% adult males in the United States, although it is difficult to know the actual extent due to the hesitancy of disclosing the problem.
  • Affected individuals may experience pain, have cord-like lesions on the penis, and exhibit abnormal curvature of the penis when erect. The abnormal curvature of the penis may make it impossible for affected individuals to have normal sexual intercourse.
  • Scleroderma is a rare, chronic disease of the immune system, blood vessels and connective tissue affecting about 2.5 million people worldwide and an estimated 300,000 people in the United States. The disease is three to four times more common in females than in males and may occur at any age but most frequently the symptoms begin in midlife. Scleroderma is an autoimmune connective tissue disorder characterized by abnormal thickening of the skin. Connective tissue is composed of collagen, which supports and binds other body tissues. Some types of sclerodermas affect certain, specific parts of the body, while other types can affect the whole body and internal organs. The exact cause of scleroderma is unknown and because the symptoms are similar to those of other autoimmune diseases, therefore diagnosis is difficult.
  • scleroderma The early symptoms of scleroderma vary considerably but distinctive abnormalities on the skin usually appear later in the course of the disease. Common symptoms include painful joints, morning stiffness, fatigue, and weight loss. People with scleroderma have areas of skin that become hard and leathery. These areas of hardness are widespread and typically appear on both sides of the body. Eventually, tissue loss occurs, and the skin becomes more highly colored. The skin can become thin, shiny, and bright which results in decreased function of the fingers and toes. Treatment of scleroderma is typically limited to symptomatic and supportive care. Medications can be administered to ameliorate the hardening of the skin, although to date they have not proven to be very effective. Skin care may include lubricating creams or antibiotic ointments for infected ulcerations.
  • Raynaud’s (or Renaud’s) phenomenon may be associated with scleroderma, although the disorder can occur in subjects without scleroderma.
  • Raynaud’s phenomenon is a vascular disorder characterized by the intermittent loss of blood to various parts of the body, particularly the fingers, toes, nose, and ears causing them to turn white. Symptoms typically occur after exposure to cold, causing tingling sensations, numbness, and pain.
  • Raynaud’s phenomenon is often an early complaint of subjects having scleroderma.
  • Collagen is a major structural component of mammalian organisms and makes up a large portion of the total protein content of skin and other parts of the mammalian body.
  • collagen is important in the wound healing process and the process of natural aging.
  • Various skin traumas such as burns, surgery, infection and accident are often characterized by the erratic accumulation of fibrous tissue rich in collagen and having increased proteoglycan content.
  • excessive and disfiguring deposits of new tissue sometimes form during the healing process.
  • the excess collagen deposition has been attributed to a disturbance in the balance between collagen synthesis and collagen degradation.
  • Fibrotic processes involved in wound healing may include topical injuries or surgical procedures. Typical topical injuries include abrasions, acute sun burns, cat scratches, chemical burns, dog bites, finger / toe nail damage, heated object burns, spider and insect bites and superficial cuts. Other topical disorders include cutaneous rashes due to allergic reactions, poison ivy, poison oak, secondary infectious rashes, including measles and chicken pox. Wounds due to surgical procedures include all wounds made in and through the skin, emergent first aid, regardless of type of surgery, skin grafts, and sutured and non-sutured incisions. Other disorders contemplated by the present invention include aged skin, sun exposed skin surfaces, and baldness.
  • oral mucosal ulceration induced by chemotherapy and/or radiation therapy.
  • oral mucosal ulceration is a common disorder for patients undergoing cancer treatment. Radiation-induced oral mucosal ulceration occurs in up to 80% of head and neck cancer irradiated patients and reaches up to 100% of patients with altered fractionation head and neck cancer.
  • Radiation-induced oral mucosal ulceration is a major dose-limiting toxicity in head and neck cancer patients. It is similar to a normal tissue injury caused by radiation, which has marked adverse effects on patient quality of life and cancer therapy continuity. It remains a challenge for proper cancer treatment because it leads to therapy interruption, poor local tumor control, and changes in dose fractionation.
  • the economic cost of oral mucosal ulceration in cancer treatment is estimated to be tens of thousands of dollars per patient being treated for head and neck cancers.
  • Aphthous Ulcers are similar to the oral mucosa! ulceration caused by cancer treatments but occur in individuals with no known cause.
  • Aphthous ulcers are small, shallow lesions that develop on the soft tissues in the mouth or at the base of the gums.
  • Aphthous ulcers do not occur on the surface of the lips and are not contagious. However, they are painful and make eating and drinking uncomfortable and difficult. Most ulcers disappear on their own within one to two weeks, but some may last longer. An effective treatment for these ulcers would greatly benefit the quality of life for those who suffer from them with some frequency.
  • the aphthous ulcers are round or oval with a white or yellow center and a red border.
  • the ulcers form inside the mouth; on or under the tongue, inside the cheeks or lips, at the base of the gums, or on the soft palate. Appearance is often accompanied by a tingling or burning sensation a day or two before the sores appear.
  • Numerous treatments for fibrosis/collagen-related diseases and disorders involve invasive procedures such as surgery or multiple injections into the affected tissue. Therefore, a topical treatment for fibrosis/collagen-related diseases and disorders highly advantageous to those suffering from the symptoms of these diseases.
  • compositions were additionally effective against more common skin and oral problems. Variations of the compositions for the orphan diseases were able to treat skin damage from cuts, abrasions, and bums; aging skin changes; and toe nail fungus. This discovery increased the population who could be helped by these compositions.
  • compositions and methods relate to treating medical conditions that are known to have few, if any, effective treatments currently available. There are many medical conditions that exist today without currently demonstrated effective medical treatments that are the subject of extensive research by major pharmaceutical companies throughout the world. The goal is to develop potentially beneficial, skin care compositions that demonstrate new effectiveness following composition component alteration and manufacturing in multiple medical conditions without known and effective treatments.
  • compositions comprising a-pinene and/or aloe vera inner leaf gel, in combination with one or more adjuvants disclosed herein, have been found to alleviate the severe symptoms of fibrosis/collagen-related diseases and disorders.
  • the present invention includes compositions and methods for the treatments of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation, and methods of manufacture thereof.
  • the present invention further includes compositions for treatment of dermal and transdermal orphan diseases and related syndromes, and methods of treatment and process of manufacture of disclosed compositions.
  • the present disclosure provides in certain embodiments novel pharmaceutical and medicinal formulations for the treatment of fibrosis/collagen-related diseases and disorders and associated pain and inflammation.
  • compositions of the present disclosure may be administered to treat, ameliorate, prevent, or cure one or more fibrotic diseases or disorder, including, Dupuytren’s disease, Dupuytren’s contracture, Ledderhose’s disease, Peyronie’s disease, scleroderma, and Raynaud’s (or Renaud’s) phenomenon, wound healing, such as skin damage from cuts, abrasions and burns, as well as aging skin changes, toe nail fungus, and chemotherapy and/or radiation induced oral mucosal ulceration, aphthous ulcers, and other diseases or conditions resulting in the excessive deposition of extracellular matrix components, such as collagen.
  • Another embodiment of the present invention is a method of treatment and/or alleviation of the pain and inflammation associated with the fibrotic diseases and disorders disclosed herein.
  • compositions according to the present disclosure may also comprise a primary fibrosis, or a condition in which said fibrosis, fibrotic condition or fibrotic symptom is secondary to or symptomatic of another condition.
  • certain embodiments comprise comprising a-pinene, aloe vera inner leaf gel, shea butter, methyl sulfonyl methane, black cumin seed oil, collagen, lecithin, glycerol, in combination with one or more adjuvants, for the treatment of the fibrosis/collagen-related diseases and disorders of the present disclosure.
  • composition comprising a-pinene is provided.
  • a composition comprising aloe vera is provided. In another embodiment, a composition comprising aloe vera inner leaf gel is provided.
  • a composition comprising shea butter is provided. In another embodiment, a composition comprising Ghana shea butter is provided.
  • a composition comprising methyl sulfonyl methane (MSM) is provided.
  • composition comprising black cumin seed oil is provided.
  • composition comprising collagen
  • composition comprising lecithin is provided.
  • composition comprising glycerol is provided.
  • the composition of the present disclosure comprises one or more adjuvants, which are comprised in the formulation, act as a vehicle, carrier, pharmaceutical carrier and/or increase the efficacy and/or potency of the composition.
  • a composition comprising one or more adjuvants selected from (s)-(-)-perillic acid, 12-hydroxydodecanoic acid, 2-hydroxy benzoate, 3- hydroxyacetophenone, 3 -hydroxybenzoic acid, 4(4’-hydroxyphenyl)-2-butanone, 4,6- dimethyl-l-heptanol, 4-ethyiphenol, 4-methoxyacetophenone, 4-methylcatechol, 5,7- dihydroxyflavanone, 5-aminosalicylic acid, 5-methoxylsalicylic acid, 6-methyl-l-heptanol, acetophenone, acetyl salicylic acid, additional:, ajoene, alipinetin, a-lipoic acid, allicin, allopurinol , allopurinol sodium, alpha tocopherol (vitamin E), alpinetin, amidoamine , apigenin, arachidonic acid, asarin
  • alpha-tocopherol salicylaldehyde, salicylamide, salicylate, salicylic acid, salsalate, salvianolic acid a, salvianolic acid a, salvianolic acid b , salvianolic acid b, sesamol, shogaol, silibinin (silybin), silymarin, sodium ascorbate, sodium erythorbate, sodium ferulate , terephthalic acid, tetrahydro-curcumin, theobromine, theophylline, tocopherol acetate vit e, tocotrienol, Trimidox, Trolox, uric acid, vanillin, verbascoside, violuric acid, vitamin e, vitamin e acetate is provided.
  • a composition comprising one or more adjuvants selected from 4-(nicotinamido) butanic acid, 5,7-dihydroxyflavanone, allicin, allopurinol, allopurinol sodium, alpha tocopherol, ammonium purrolidyldithiocarbamate, anisodamine, arachidonic acid, asarinin (desmin), ascorbic acid (vitamin C), ascorbyl palmitate, bemethyl, betacarotene, bilirubin, bromovanillin, butylated hydroxytoluene, butyric acid, caffeic acid, calcium ascorbate, carvacrol, chlorovanillin, Chromal, chromanol, cianidanol (catechin), cyanidin, cyani din-3 -glucose, diallyl sulfide, dihydroferulic acid, dihydrolipoic acid, dimethyl sulfox
  • composition comprising one or more adjuvants selected from 6-shagaol, ajoene, baicalin, gastrodin, genipin, halofuginone, kynurenic acid, lycopene, mofebutazone, obavatol, perillic acid, rhein is provided.
  • composition comprising one or more adjuvants selected from alipinetin, bicalin, glyceollin 1, hesperidin glycoside, hesperitin, icariin, morelloflavon, murrayafoline A, naringenin, naringin, pinocembrin, puerarin, quercitin is provided.
  • adjuvants selected from alipinetin, bicalin, glyceollin 1, hesperidin glycoside, hesperitin, icariin, morelloflavon, murrayafoline A, naringenin, naringin, pinocembrin, puerarin, quercitin
  • a composition comprising one or more adjuvants selected from 3 -hydroxy acetophenone, 3 -hydroxybenzoic acid, 4(4'-hydroxyphenyl)-2-butanone, 4,6- dimethyl-l-heptanol, 4-ethyiphenol, 4-methoxyacetophenone, 4-methylcatechol, 5- methoxylsalicylic acid, 6-methyl-l-heptanol, acetophenone, benzoic acid, benzyl alcohol, borneol, castoramine, catechol, cyclohexane- 1,2, -diol, hydroquinone, isopinocamphone, linalool alkaloid, linalool oxide a, nupharamine , o-creosol, phenol, pinocamphone, salicylaldehyde is provided.
  • a composition comprising one or more adjuvants selected from 3 -hydroxy acetophenone, 3 -hydroxybenzoic acid, 4,6-dimethyl-l-heptanol, 4- ethyiphenol, 4-methoxyacetophenone, 4-methylcatechol, 5-methoxylsalicylic acid, 6-methyl- l-heptanol, acetophenone, catechol, isopinocamphone, linalool alkaloid, linalool oxide a, pinocamphone, salicylaldehyde is provided.
  • adjuvants selected from 3 -hydroxy acetophenone, 3 -hydroxybenzoic acid, 4,6-dimethyl-l-heptanol, 4- ethyiphenol, 4-methoxyacetophenone, 4-methylcatechol, 5-methoxylsalicylic acid, 6-methyl- l-heptanol, acetophenone, catechol, isopinocamphone, linalool alkaloid,
  • composition comprising one or more adjuvants selected from 3 -hydroxy acetophenone, 3 -hydroxybenzoic acid, 4-ethyiphenol, 4- methoxyacetophenone, 4-methylcatechol, 5-methoxylsalicylic acid, acetophenone, catechol, salicylaldehyde is provided.
  • composition comprising one or more adjuvants selected from 3 -hydroxy acetophenone, 4-ethyiphenol, acetophenone, catechol is provided.
  • composition comprising 4-(nicotinamido) butanic acid is provided.
  • composition comprising alpha tocopherol is provided.
  • composition comprising ammonium purrolidyldithiocarbamate is provided.
  • composition comprising asarininn is provided.
  • composition comprising bilirubin is provided.
  • a composition comprising bromovanillin is provided.
  • composition comprising butylated hydroxytoluene is provided.
  • a composition comprising caffeic acid is provided.
  • a composition comprising chlorovanillin is provided.
  • composition comprising Chromal is provided.
  • composition comprising diallyl sulfide is provided.
  • composition comprising dihydrolipoic acid is provided.
  • composition comprising dimethyl sulfoxide is provided.
  • composition comprising DL-alpha-tocopherol acetate is provided.
  • a composition comprising feruic acid is provided.
  • a composition comprising hydroxytyrosol is provided.
  • composition comprising lithospermate B is provided.
  • composition comprising lycopene is provided.
  • a composition comprising manganese-platinum organic complexes (e.g., MNTP-Bio2 and MNT4MPYP) is provided.
  • manganese-platinum organic complexes e.g., MNTP-Bio2 and MNT4MPYP
  • composition comprising melatonin is provided.
  • composition comprising nicareven is provided.
  • composition comprising proamipider.
  • composition comprising probucol is provided.
  • composition comprising rebamipide is provided.
  • composition comprising reservatrol is provided.
  • composition comprising rosmarinic acid is provided.
  • composition comprising Sesamol is provided.
  • a composition comprising Silibyn (silininin) is provided.
  • composition comprising sodium terephthalate is provided.
  • composition comprising terephthalic acid is provided.
  • composition comprising thicotic acid is provided.
  • composition comprising trans-caffeic acid is provided.
  • a composition comprising Trimidox (vetoquinol) is provided.
  • composition comprising Trolox is provided.
  • composition comprising Tyrosol is provided.
  • a composition comprising uric acid is provided.
  • a composition comprising vanillin is provided.
  • composition comprising violuric acid is provided.
  • composition comprising vitamin E is provided.
  • composition comprising vitamin E acetate is provided.
  • a composition comprising one or more adjuvants selected from 1,2-hexanediol, 1,2-octanediol (caprylyl glycol), 1 -tetradecanol, a phycobiliprotein, acai berry oil, agave nectar, ajwain oil, alanine, almond oil, Aloe vera inner leaf gel, alpha- cadinol, anethole oil, anise seed oil, annato, apricot kernal oil, arachidonic acid, arctic fish (AF) collagen, argan nut oil, arginine, atlas cedar wood oil , baobab oil, bayberry wax, bees wax, benzoic acid, benzoin, benzyl alcohol, berberine, betaine, bixin, black cumin seed oil, Boesenbergia rotunda, cajuput or cajeput oil, calendula oil, camellia
  • a composition comprising one or more adjuvants selected from apricot kernal oil, argan nut oil, baobab oil, calendula oil, camellia oil , caprylic capric triglyceride, caryophyllene, elemi oil, kanuka oil, litsea cubeba oil, marula oil, palmarosa oil, palo santo, rose hip seed oil, sachi inchi oil, sea buckthorn oil, tamanu oil is provided.
  • adjuvants selected from apricot kernal oil, argan nut oil, baobab oil, calendula oil, camellia oil , caprylic capric triglyceride, caryophyllene, elemi oil, kanuka oil, litsea cubeba oil, marula oil, palmarosa oil, palo santo, rose hip seed oil, sachi inchi oil, sea buckthorn oil,
  • composition comprising one or more adjuvants selected from acai berry, chamomile german oil, copaiba oil, linoleic acid, myrrh, oleic acid, rose hip seed oil is provided.
  • composition comprising one or more adjuvants selected from anethole anise camphor, cabreuva oil, carvacrol, floral, niaouli oil, rosemary oil, thyme red, white winter savory is provided.
  • composition comprising one or more adjuvants selected from benzyl alcohol, cetyl alcohol, panthenol is provided.
  • composition comprising one or more adjuvants selected from caffeic acid, kaempferol, protocatechuic acid is provided.
  • composition comprising one or more adjuvants selected from bees wax, benzoin, benzocaine, cedarwood essential oil, ferulic Acid, is provided.
  • composition comprising one or more adjuvants selected from carvone oil, geranium oil, ho wood oil, jasmine oil, lavandin oil, limonene oil, nerolina oil, peppermint, terpineol, and vetiver is provided.
  • composition comprising one or more adjuvants selected from alanine, arginine, glutamine, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, praline is provided.
  • a composition comprising one or more adjuvants selected from vitamin A, vitamin B3, niacin, vitamin C, vitamin E, niacinamide is provided.
  • a composition comprising one or more adjuvants selected from Agave nectar, distilled water, Sericin, Sodium Polyacrylate, 1 -Tetradecanol is provided.
  • a composition comprising one or more adjuvants selected from a-pinene, 1 -tetradecanol, acai berry, agave, alanine, anethole anise camphor, apricot kernal oil, argan nut oil, arginine, soluble collagen, arctic fish (AF) collagen, baobab oil, bees wax, benzocaine, benzoin, benzyl alcohol, black cumin seed, cabreuva oil, caffeic acid, calendula oil, camellia oil, caprylic, capric triglyceride, carvacrol, carvone oil, caryophyllene, cedarwood essential oil, cetyl alcohol, chamomile german oil, copaiba oil, elemi oil, ferulic acid, geranium oil, Ghana shea butter, glutamine, glycerol, glycine, histidine, ho wood oil, hydroxyproline, isole
  • a composition comprising one or more adjuvants selected from aloe barbadensis (aloe vera) leaf extract, butyrospermum parkii butter (shea butter), alpha pinene, black cumin seed oil, tri (polyglyceryl-3/lauryl) hydrogenated trilinoleate, methyl sulfonyl methane (MSM), sodium hydroxide, betaine, carvacrol, magnesium sulfate, camellia oil, caryophyllene, caprylyl glycol, 1,2-hexanediol, apricot oil, argan oil, sea buckthorn oil, tamanu oil, sodium pyroglutamic acid (PCA), caprylic/capric triglyceride, copaiba oil, roman chamomile oil, linoleic acid, oleic acid, propylene glycol, ferulic acid, sodium lactate, baobab oil, marula oil
  • adjuvants selected
  • the composition of this disclosure comprises one or more of a- pinene, aloe vera inner leaf gel, shea butter, collagen, methyl sulfonyl methane, lecithin, glycerol, and one or more adjuvants of the present disclosure.
  • the composition of this disclosure comprises from about 1.0 to about 5.0 wt. % a-pinene, from about 0.1 to about 1.0 wt. % 1 -tetradecanol, from about 1.0 to about 5.0 wt. % collagen, from about 0.1 to about 3.0 wt. % agave nectar, from about 0.1 to about 2.0 wt.
  • % alanine from about 10.0 to about 20.0 wt. % aloe vera inner leaf gel, from about 0.1 to about 2.0 wt. % apricot kernal oil, from about 0.1 to about 2.0 wt. % argan nut oil, from about 0.1 to about 2.0 wt. % arginine, from about 0.1 to about 1.0 wt. % baobab oil, from about 1.0 to about 5.0 wt. % bees wax, from about 0.1 to about 2.0 wt. % benzoin, from about 1.0 to about 5.0 wt. % benzyl alcohol, from about 1.0 to about 5.0 wt.
  • % black cumin seed oil from about 0.1 to about 3.0 wt. % calendula oil, from about 0.1 to about 3.0 wt. % camellia oil, from about 0.1 to about 3.0 wt. % caprylic, capric triglyceride, from about 0.1 to about 3.0 wt. % carvacrol, from about 0.1 to about 3.0 wt. % caryophyllene, from about 1.0 to about 5.0 wt. % cetyl alcohol, from about 0.1 to about 3.0 wt. % chamomile german oil, from about 0.1 to about 3.0 wt. % copaiba oil, from about 20 to about 35.0 wt.
  • % distilled water from about 0.1 to about 3.0 wt. % elemi oil, from about 0.1 to about 3.0 wt. % ferulic acid, from about 0.1 to about 1.0 wt. % geranium oil, from about 10.0 to about 20.0 wt. % shea butter, from about 0.1 to about 3.0 wt. % glutamine, from about 0.1 to about 3.0 wt. % glycerol, from about 0.1 to about 2.0 wt. % glycine, from about 0.1 to about 2.0 wt. % histidine, from about 0.1 to about 1.0 wt. % ho wood oil, from about 0.1 to about 2.0 wt.
  • % hydroxyproline from about 0.1 to about 2.0 wt. % isoleucine, from about 0.1 to about 1.0 wt. % jasmine oil, from about 0.1 to about 1.0 wt. % kanuka oil, from about 0.1 to about 3.0 wt. % lavandin oil, from about 0.5 to about 4.0 wt. % lecithin, from about 0.1 to about 2.0 wt. % leucine, from about 1.0 to about 5.0 wt. % limonene oil, from about 0.1 to about 2.0 wt. % linoleic acid, from about 0.1 to about 2.0 wt.
  • % litsea cubeba oil from about 0.1 to about 2.0 wt. % lysine, from about 0.1 to about 1.0 wt. % marula oil, from about 0.5 to about 3.0 wt. % methyl sulfonyl methane, from about 0.1 to about 1.0 wt. % nerolina oil, from about 0.1 to about 1.0 wt. % niacinamide, from about 0.1 to about 2.0 wt. % oleic acid, from about 0.1 to about 1.0 wt. % palmarosa oil, from about 0.1 to about 3.0 wt. % panthenol, from about 0.1 to about 2.0 wt.
  • % praline from about 0.1 to about 3.0 wt. % protocatechuic acid, from about 0.1 to about 2.0 wt. % rosemary oil, from about 0.1 to about 2.0 wt. % sea buckthorn oil, from about 1.0 to about 5.0 wt. % sericin, from aboutO.l to about 3.0 wt. % sodium polyacrylate, from about 0.1 to about 2.0 wt. % tamanu oil, from about 0.1 to about 1.0 wt. % vitamin A, from about 0.1 to about 3.0 wt. % Vitamin B3 (niacin), from about 0.1 to about 1.0 wt. % vitamin C, and from about 0.1 to about 1.0 wt.
  • a-Pinene is a hydrophobic compound found in nature.
  • a-pinene is provided as a colorless liquid with a pine, turpentine-like odor.
  • a- pinene is from a natural source.
  • a-pinene is from a synthetic source, a-pinene is reported to have a specific gravity at 25 °C of 0.8550-0.8600, a refractive index at 20 °C of 1.4640-1.4680, an optical rotation of 20.00-30.00.
  • a- pinene is provided without the presence of salmonella (AO AC, negative), lead, aflatoxin, arsenic, or mercury detected.
  • a-pinene is about 95 % pure, preferably 99 % pure, and more preferably about 99.5-100% pure. In one embodiment, pure a-pinene is obtained from Flavorchem Orchidia Fragrances, Downers Grove, IL, USA.
  • a composition of the present disclosure comprises about 0.1 to about 50.0 wt. % a-pinene. In another embodiment, a composition of to the present disclosure comprises about 0.5 to about 20.0 wt. % a-pinene, about 1.0 to about 10.0 wt. % a- pinene, about 2.0 to about 7.0 wt. % a-pinene, or about 3.0 to about 4.0 wt. % a-pinene. In another embodiment, the composition of the present invention comprises 1.0 wt. % a-pinene, 2.0 wt. % a-pinene, 3.0 wt. % a-pinene, 4.0 wt.
  • % a-pinene 5.0 wt. % a-pinene, 6.0 wt. % a- pinene, 7.0 wt. % a-pinene, 8.0 wt. % a-pinene, 9.0 wt. % a-pinene, 10.0 wt. % a-pinene, 11.0 wt. % a-pinene, 12.0 wt. % a-pinene, 13.0 wt. % a-pinene, 14.0 wt. % a-pinene or 15.0 wt. % a-pinene.
  • a composition of the present disclosure comprises from about 1.0 to about 5.0 wt. % a-pinene.
  • an “aloe vera” of the present disclosure may be prepared or otherwise derived from leaves of the aloe vera plant, otherwise known as Aloe barbadensis.
  • an aloe vera preparation is a hydrophilic component of a composition of the present disclosure.
  • an aloe vera preparation is and/or includes gel taken from the inner portion of aloe vera leaves (also known as “aloe vera inner leaf gel”), for instance as described above.
  • Aloe vera inner leaf gel is a gel that comprises proteins, lipids, amino acids, vitamins, enzymes, inorganic compounds, organic compounds, and carbohydrates.
  • the gel may be in its natural form, taken directly from the aloe vera leaf, or for instance in a processed form, for instance as a 10X or 200X concentrated dried powder.
  • an aloe vera preparation of this disclosure may include part of or all of whole aloe vera leaves, for instance in the form of aloe vera leaf juice or an aloe vera leaf extract.
  • An aloe vera preparation that is or includes leaf juice or is or includes leaf extract may also be in a concentrated form, for instance in a 10X or 200X dried powder.
  • an aloe vera preparation of the present disclosure does not include the aloin or yellow or brown latex portion of the aloe leaf, and/or does not include the dark green outer covering of the leaf.
  • the aloe vera inner leaf gel is in powder form, 200x concentrated.
  • the 200x powder may be a spray-dried, light-cream -to-beige colored powder, having characteristics such as pH(l : 199 w/w) 3.5-5.0, specific gravity(l : 199 w/w) 0.997- 1.004, 8% maximum moisture, 100% particle size through 80 mesh, certifications such as is made from pure aloe i.e. does not include fillers and/or adulterants, and/or has no pathogens present ( ⁇ 10 cfu/g total plate count, ⁇ 10 cfu/g yeast and mold).
  • the 200x aloe vera inner leaf gel powder is spray-dried to 200x the concentration of aloe vera inner leaf gel, is light cream to beige powder, pH 4.5, specific gravity (1 : 199 w/w) 1.001, about 4-5% moisture (water), 100% particle size through 80 mesh, is pure aloe i.e. does not include fillers and/or adulterants, and has no pathogens present ( ⁇ 10 cfu/g total plate count, ⁇ 10 cfu/g yeast and mold).
  • the aloe vera preparation is Terra-PureTM Certified Spray Dried Aloe Vera Inner Leaf Powder Regular, 200X (Terry Laboratories, Melbourne FL, USA).
  • an aloe vera preparation including a 200x aloe vera preparation comprises or consists of inner leaf juice, made by removing the rind of the leaf prior to processing and then rinsing away aloe latex. The remaining, gelatinous inner-leaf material is then ground/crushed into aloe vera inner leaf juice.
  • aloe vera includes other parts of the aloe vera plant.
  • the aloe vera preparation may be a powder made from Aloe barbadensis leaf juice (e.g., CAS 94349-62-9).
  • leaf juice is extracted from fresh aloe leaves with a juice extractor, decolorized and filtered, separated via organic membrane. The membrane-separated concentrate juice is then freeze dried to be converted into the 200: 1 Aloe Vera freeze dried gel powder.
  • an aloe vera preparation according to the present disclosure is Aloe Vera freeze dried gel powder 200: 1 (Selco, Wald-Michelbach, Germany).
  • 200: 1 aloe powder includes about 0.5% soluble solid of Aloe Vera gel.
  • 200 kg of 1 : 1 Aloe Vera gel juice is frozen and dried into 1kg of Aloe Vera freeze dried gel powder that becomes Aloe vera 200: 1.
  • aloe vera is a 200X powder produced through the water extraction of Aloe barbadensis leaf to prepare leaf juice powder.
  • aloe leaves are harvested, washed and filtered, aloin removed from filets, then the leaves ground, excess pulp removed, treated with heat, filtered, and spray dried.
  • Aloe vera according to the present disclosure in unconcentrated or concentrated (e.g., 200X) form, is a hydrophilic component/ingredient of this disclosure. While 200X concentrated powders are a preferred embodiment according to the present disclosure, other concentrations may also be included in the present disclosure.
  • 200X concentrated powders are a preferred embodiment according to the present disclosure, other concentrations may also be included in the present disclosure.
  • aloe vera preparations of the present disclosure include aloe polysaccharides consisting of linear (unbranched) chains of b-l-4-linked glucose and mannose molecules (often called glucomannans, and because more mannose than glucose is present, polymannans). These linear chains range from a few molecules to several thousand molecules. By convention, the lower limit is usually taken as a molecular weight of about 1,000 Daltons for the material to qualify as a polysaccharide.
  • aloe vera preparations for instance as provided by Terry Laboratories are microbiologically clean, color stable, processed as quickly as possible following harvest, and processed at the lower temperature possible.
  • the aloe vera preparation including for instance 10X or 200X aloe vera preparations retains polysaccharide molecular weight distribution comparable to unprocessed aloe vera and reduces polysaccharide degradation such that not less than 50% of polysaccharides are greater than 1 million Daltons.
  • an aloe vera preparation includes acemannan (beta-l-4-acetylated glucomannans).
  • a composition of the present disclosure comprises about 0.1 to about 50.0 wt. % aloe vera.
  • a composition according to the present invention includes about 5.0 to about 30 wt. % aloe vera, about 10.0 to about 20.0 wt. % aloe vera, about 13.0 to about 18.0 wt. % aloe vera, about 14.0 to about 16.0 wt. % aloe vera, or about 15.0 wt. % aloe vera.
  • the aloe vera preparation may have its natural concentration, IX, single-strength equivalent form, or in a concentrated 10X, 200X, or other concentrated form.
  • the composition of the present disclosure comprises “shea butter.”
  • Shea butter and/or oil extracted from shea butter (“shea butter oil”), is prepared from or otherwise derived from any Shea tree, including but not limited to a Shea tree from Ghana.
  • shea butter or shea butter oil is Butyrospermum parkii butter (CAS 194043-92-0; EC 293-515-7); Butyrospermum parkii oil (CAS 91080-23-8, EC 293-515-7), and/or vegetable oil (CAS 68956-68-3, EC 273-313-5).
  • Other shea butters and shea butter oils may be used in shea butter preparations of this invention, including those having different CAS or EC, or other identifying numbers.
  • Shea butter oil is prepared by a series of processes including mechanical extraction, solvent extraction, refinement, deodorization, and solvent fractionation.
  • Shea tree nuts undergo mechanical pressing and solvent extraction with hexane to prepare crude oil, which is then subjected to degumming with acidified water (phosphoric or citric acid) (degumming removes phospholipids, metals, and proteins), neutralization with alkaline water (sodium hydroxide) (neutralization removes free fatty acids, metals, and proteins), and bleaching with bleaching earth (clay) and citric acid (bleaching removes pigments, metals, and proteins) to prepare a bleached oil.
  • acidified water phosphoric or citric acid
  • alkaline water sodium hydroxide
  • bleaching earth clay
  • citric acid bleaching removes pigments, metals, and proteins
  • the bleached oil is mixed with solvent and cooled (separating solid and liquid constituents), filtered, solvent (hexane and/or acetone) recovered; and then deodorized with steam (removes flavors, free fatty acids, oxidation products and residual solvent).
  • Shea butter oil according to the present preparation is liquid at room temperature, has a red color, a density (25°C) of 0.9-0.94 g/cm3, a fatty acid composition (w/w) for instance as follows: 5% C16:0, 28% C18:0, 56% C18:l, 9% C18:2, 0.3% C18:3, 1% C20:0, 1% C22:0, available as Lipex SheaLiquidTM (AAK Sweden AB, Karlshamn, Sweden, SE-374-82).
  • a composition of the present disclosure comprises about 10.0 to about 20.0 wt. % aloe vera inner leaf gel.
  • the composition of the present disclosure comprises about 0.1 to about 50.0 wt. % shea butter.
  • the composition of the present disclosure comprises about 1.0 to about 30.0 wt. % shea butter, about 8.0 to about 20.0 wt.% shea butter about 12.0 to about 18.0 wt. % shea butter, about 14.0 to about 16.0 wt. % shea butter, or about 15.0 wt. % shea butter.
  • the composition of the present disclosure comprises about 1.0 to about 20.0 wt. % shea butter, wherein the preparation is shea butter oil, about 2.0 to about 15.0 wt. % w/w shea butter oil, about 3.0 to about 8.0 wt. % shea butter oil, or about 4.0 to about 6.0 wt. % shea butter oil.
  • a composition of the present disclosure comprises from about 10.0 to about 20.0 wt. % shea butter.
  • the composition of the present disclosure comprises soluble collagen.
  • soluble collagen such as IchtyocollagenTM, comprises native fish collagen.
  • IchtyocollagenTM has film-forming and moisturizing, skin conditioning properties.
  • IchtyocollagenTM is provided in liquid form at 25 °C, colorless to pale yellow, with appearance clarity of clear to slightly opalescent.
  • ichtyocollagen comprises 0.4-0.7% protein (by BCA), pH 3.5-4.5, specific gravity at 20 °C of 1.000-1.020, refractive index at 25 °C of 1.34-1.36, hydroxyproline content 0.06-0.09%, and/or maximum 100CFU/G total aerobic microbial count and maximum 10 CFU/G total combined yeast/mold count.
  • IchtyocollagenTM comprises soluble collagen (INCI), CAS 9007-34-5, EINECS 232-697-4, as well as propylene glycol (approx. 10%), phenoxyethanol (1.5%), potassium sorbate (0.05%), trisodium EDTA (0.1%).
  • IchtyocollagenTM includes about 88% of natural origin content.
  • the composition of the present disclosure comprises IchtyocollagenTM PH (Croda/Sederma Inc., Edison, NJ, USA)
  • a composition of the present disclosure comprises from about 1.0 to about 5.0 wt. % collagen, from about 3.0 to about 10.0 wt. % collagen, from about 8.0 to about 115.0 wt. % collagen, and , from about 10.0 to about 25.0 wt. % collagen.
  • a composition of the present disclosure comprises from about 0.5 to about 3.0 wt. % methyl sulfonyl methane.
  • a composition of the present disclosure comprises from about 1.0 to about 5.0 wt. % black cumin seed oil.
  • a composition of the present disclosure comprises from about 0.5 to about 4.0 wt. % lecithin.
  • a composition of the present disclosure comprises from about 0.1 to about 3.0 wt. % glycerol.
  • the present disclosure also provides pharmaceutical formulations of the disclosed compositions.
  • the pharmaceutical formulations comprise a therapeutically effective amount of a composition of the present disclosure formulated with one or more pharmaceutically acceptable carriers and/or excipients.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and, more particularly, in humans.
  • the term “pharmaceutically acceptable” means suitable for use in mammals.
  • compositions of the present invention may be formulated for administration by a variety of routes including oral, rectal, transdermal, parenteral (subcutaneous, intraperitoneal, intravenous, intraarterial, transdermal and intramuscular), topical, intranasal, or via a suppository.
  • routes including oral, rectal, transdermal, parenteral (subcutaneous, intraperitoneal, intravenous, intraarterial, transdermal and intramuscular), topical, intranasal, or via a suppository.
  • Such compositions are prepared in a manner well known in the pharmaceutical art and comprise as an active ingredient at least one compound of the present invention as disclosed herein, and a pharmaceutically acceptable excipient or carrier.
  • topical formulations may be used and may include pharmaceutically acceptable preservatives, surfactants, viscosity enhancers, buffers, sodium chloride, and water to form aqueous pharmaceutically compatible solutions and suspensions.
  • Suitable topical formulations are known in the art, for example, as described in text books and review articles, e.g., Benson, et al., Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies, Current Drug Delivery, 2019, 16(5) pgs. 444- 460.
  • Suitable ophthalmological formulations are also known in the art and described in text books and review articles, e.g., “Recent Advances in Topical Ocular Drug Delivery", by V.K. Yellepeddi and S. Palakurthi (J. Ocul. Pharmacol. Ther. 2016, 32(2):67-82), herein incorporated by reference in its entirety.
  • Systemic formulations for example, orally ingested tablets
  • formulations for intraocular injection are also contemplated, (pharmaceutically acceptable carriers). Examples of suitable pharmaceutically acceptable excipients and carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in the pharmaceutical field, herein incorporated by reference in its entirety.
  • composition excipients may be any excipient known in the art and are limited only by chemi cal -physical considerations, such as solubility and lack of reactivity with the compound for use in the present disclosure, and by the route of administration. The choice of excipient is determined by the particular method/route used to administer the pharmaceutical composition.
  • suitable pharmaceutical excipients include lactose, glucose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water and methylcellulose.
  • the formulations of the present disclosure may additionally include lubricating agents such as talc, magnesium stearate, and mineral oil, wetting agents, surfactants, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents, flavoring agents, colorants, buffering agents (e.g., acetates, citrates or phosphates), disintegrating agents, moistening agents, antibacterial agents, antioxidants (e.g., ascorbic acid or sodium bisulfite), chelating agents (e.g., ethylenediaminetetraacetic acid), and agents for the adjustment of tonicity such as sodium chloride.
  • lubricating agents such as talc, magnesium stearate, and mineral oil
  • wetting agents such as talc, magnesium stearate, and mineral oil
  • surfactants emulsifying and suspending agents
  • preserving agents such as methyl- and propylhydroxybenzoates
  • sweetening agents e.g
  • compositions of the present disclosure may be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents.
  • water is a preferred excipient when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions may also be employed as liquid excipients, particularly for injectable solutions.
  • the term “pharmaceutically acceptable salts” refers to either “pharmaceutically acceptable acid addition salts” or “pharmaceutically acceptable basic addition salts”.
  • the term “salt” or “salts” may refer to “pharmaceutically acceptable salts” or to salts suitable for use in industrial processes, that might not be pharmaceutically acceptable.
  • pharmaceutically acceptable acid addition salts refer to non-toxic organic or inorganic acid addition salt of the base compounds disclosed herein or any of their intermediates.
  • Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric, and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate, and potassium hydrogen sulfate.
  • Illustrative organic acids which form suitable salts include the mono-, di-, and tricarboxylic acids.
  • Illustrative of such acids are for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxy-benzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid, and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid.
  • Such salts may exist in either a hydrated or substantially anhydrous form.
  • the acid addition salts of these compounds are soluble in water and various hydrophilic organic solvents.
  • pharmaceutically acceptable basic addition salts refers to non-toxic organic or inorganic basic addition salts of the compounds disclosed herein.
  • Illustrative bases which form suitable salts include alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium, or barium hydroxides; ammonia, and aliphatic, alicyclic, or aromatic organic amines such as methylamine, dimethylamine, trimethylamine, and picoline.
  • compositions of the present disclosure also comprise solvates of the compounds herein.
  • “Solvates” include physical associations of a compound of the disclosure with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate may be capable of isolation.
  • the term “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates and the like.
  • a “hydrate” is a solvate wherein the solvent molecule is water.
  • any range disclosed as a whole number is understood to include the whole numbers between the stated range.
  • the range of about 10 to about 20 discloses the ranges about 10 to about 11, about 11 to about 12, about 12 to about 13, about 13 to about 14, about 14 to about 15, about 15 to about 16, about 16 to about 17, about 17 to about 18, about 18 to about 19, and about 19 to about 20.
  • any range disclosed to one-tenth is understood to include the whole numbers and one-tenth numbers between the stated range.
  • the range of about 0.0 to about 1.0 discloses the ranges about 0.0 to about 0.1, about 0.1 to about 0.2, about 0.2 to about 0.3, about 0.3 to about 0.4, about 0.4 to about 0.5, about 0.5 to about 0.6, about 0.6 to about 0.7, about 0.7 to about 0.8, about 0.8 to about 0.9, and about 0.9 to about 1.0.
  • compositions of the present disclosure may include one or more buffering agent(s) or pH adjusting agent(s) to provide improved pH control.
  • a composition of this disclosure has a pH between about 5.0 and about 8.0, between about 5.0 and about 7.0, between about 6.0 and about 8.0, or between about 6.0 and about 7.0.
  • the pH of a composition of this disclosure is from about 5.3 to about 7.3.
  • the pH of a composition of this disclosure is from about 5.3 to about 6.3.
  • the pH of a composition of this disclosure is from about 6.3 to about 7.3.
  • a composition of this disclosure has an approximately neutral pH of about 6.8 to about 7.2.
  • the pH of a composition of this disclosure is from about 5.3 to about 5.8. In yet another embodiment, the pH of a composition of the present disclosure is about 5.5. In yet another embodiment, the pH of a composition of the present disclosure is optimized as known by those of skill in the art, see, e.g., Lukic, et al., Towards Optimal pH of the Skin and Topical Formulations: From the Current State of the Art to Tailored Products, Cosmetics, 2021, 8, 69, pgs. Rl-19.
  • At least one of the excipients is a non-aqueous excipient.
  • compositions of the present invention may further comprise optional components such as lipid carriers such as oils or waxes so as to provide a semi-solid consistency as desired. Additional inactive excipients such as preservatives, antioxidants, perfumes, and the like may also be added.
  • lipid carriers such as oils or waxes so as to provide a semi-solid consistency as desired.
  • Additional inactive excipients such as preservatives, antioxidants, perfumes, and the like may also be added.
  • Oils that may be used as optional components in the compositions of the present invention include, but are not limited to, petrolatum (petroleum jelly), vegetable oil, fruit oil, plant oil, animal oil, mineral oil, coconut oil, olive oil, lanolin, peanut oil, hydrogenated and sulphated oils such as cottonseed oil, soybean oils, almond oil, sesame oil, and the like.
  • the oil comprises com oil, peanut oil, coconut oil, grape seed oil, sunflower oil, lemon oil, orange oil, peppermint oil, palm kernel oil, castor oil, hydrogenated cottonseed oil, hydrogenated soy oil, hydrogenated soybean oil, hydrogenated vegetable oil, partially hydrogenated soybean oil, partially hydrogenated palm oil, hydrogenated castor oil, light mineral oil, mineral oil, or a combination thereof.
  • Waxes that may be used as optional components in the compositions of the present invention include, but are not limited to, paraffin wax, beeswax, carnauba wax, cetyl ester wax, microcrystalline wax, spermaceti wax, and the like.
  • contemplated excipients which may be utilized in the pharmaceutical compositions of this disclosure include, for example, antimicrobial agents, antioxidants, antistatic agents, lipids such as phospholipids or fatty acids, steroids such as cholesterol, protein excipients such as serum albumin (human serum albumin), recombinant human albumin, gelatin, casein, salt-forming counterfoils such sodium and the like.
  • the composition is prepared for topical administration.
  • the topical composition comprises an ointment.
  • the topical composition comprises a cream.
  • the topical composition comprises a lotion.
  • the topical composition comprises a balm.
  • the topical composition comprises a gel.
  • the topical composition comprises a paste.
  • the topical composition comprises a drop.
  • the topical composition comprises a foam.
  • the topical composition comprises a powder, solution.
  • the topical composition comprises a spray.
  • the topical composition comprises a patch.
  • the components of the topical formulation are admixed under various conditions, including sterile conditions, with a pharmaceutically acceptable excipient and any needed preservatives or buffers as may be required.
  • compositions of the present disclosure can be prepared and applied in a physiologically acceptable diluent with or without a pharmaceutical carrier.
  • the ointment, cream, lotion, balm, gel, paste, drop, foam, powder, solution, spray, or patch of the present disclosure may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Adjuvants for topical formulations may include, for example, sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol and wood wax alcohols.
  • Powders and sprays may contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays may additionally contain customary propellants such as chlorofluorohydrocarbons.
  • a composition of the present disclosure is a water-in- oil emulsion comprising water and an emulsifier.
  • water is distilled water, and comprises about 25 to about 70 wt. % of the emulsion and the composition. In an embodiment, water comprises about 25 to about 50 wt. % or about 50 to about 70 wt. % of the emulsion.
  • an emulsifier is tri-(polyglyceryl-3/lauryl) hydrogenated trilinoleate (Cithrol PGTL), polyglyceryl-3 sorbityl linseedate (Sinerga), polyglyceryl-2 oleate, polyhydroxystearic acid, polyglyceryl-2 stearate (Innovacos), Polyglyceryl-3 Triolivate (Acme Hardesty), polyglyceryl-3 polyricilinoleate (IOI Oleo), polyglyceryl-2 dipolyhydroxystearate (BASF), polyglyceryl-2 sesquiisostearate (Clariant), polyglyceryl-3 diisostearate (Gattefosse, BASF), polyglyceryl-6 polyricinoleate (and) polyglyceryl-3 diisostearate (and) Disteardimonium Hectorite (Elementis), Olive Oil Polyglyceryl-6 Esters (and) Polyglyceryl-6 Pen
  • a water-in-oil emulsion of the present disclosure comprises about 0.1 to about 10.0 wt. % emulsifier, about 0.5 to about 5.0 wt. % emulsifier, about 1.0 to about 3.0 wt. % emulsifier, or about 1.0 to about 2.0 wt. % emulsifier.
  • the water-in-oil emulsion is a topical composition.
  • Alternative formulations include nasal sprays, liposomal formulations, dendrimer formulations, slow-release formulations, controlled-release formulations, and the like, as are known in the art.
  • liposomal formulations is known in the art and have been described for use in the development of topical formulations, see. e.g., Castaneda-Reyes, et al., Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review, Int J Nanomedicine, 2020, 15, pgs.7627-7650.
  • dendrimer formulations are known in the art and have been described for use in the development of topical formulations, see. e.g., Pentek, et al., Development of a Topical Resveratrol Formulation for Commercial Applications Using Dendrimer Nanotechnology, Molecules, 2017, 22(1), pg. 137.
  • transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present disclosure in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms may be made by dissolving or dispensing the components disclosed herein in a proper medium.
  • Absorption enhancers may also be used to increase the flux of the compound across the skin.
  • the rate of release may also be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of palmar fascia fibromatosis. Another embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of Dupuytren’s disease. Yet another embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of Dupuytren’s contracture.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of Ledderhose’s disease.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of Peyronie’s disease.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of scleroderma.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of Raynaud’s (or Renaud’s) phenomenon.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of wound healing, such as skin damage from cuts, abrasions and burns, as well as aging skin changes.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of toe nail fungus.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of chemotherapy and/or radiation induced oral mucosal ulceration.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of aphthous ulcers.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of fibrotic processes involved in wound healing including topical injuries and wounds from surgical procedures.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of topical injuries including abrasions, acute sun burns, cat scratches, chemical burns, dog bites, finger / toe nail damage, heated object burns, spider and insect bites and superficial cuts.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of topical disorders including cutaneous rashes due to allergic reactions, poison ivy, poison oak, secondary infectious rashes, including measles and chicken pox.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of wounds due to surgical procedures including all wounds made in and through the skin, emergent first aid, regardless of type of surgery, skin grafts, and sutured and non-sutured incisions.
  • One embodiment of the present disclosure is a method for the alleviation of symptoms and/or the treatment of disorders including aged skin, sun exposed skin surfaces, and baldness.
  • Fibrotic processes involved in wound healing may include topical injuries or surgical procedures. Typical topical injuries include abrasions, acute sun burns, cat scratches, chemical burns, dog bites, finger / toe nail damage, heated object burns, spider and insect bites and superficial cuts. Other topical disorders include cutaneous rashes due to allergic reactions, poison ivy, poison oak, secondary infectious rashes, including measles and chicken pox. Wounds due to surgical procedures include all wounds made in and through the skin, emergent first aid, regardless of type of surgery, skin grafts, and sutured and non-sutured incisions. Other disorders contemplated by the present invention include aged skin, sun exposed skin surfaces, and baldness.
  • the present invention may be used topically or transdermally.
  • the term “administering” or “administration” refers to bringing into contact with a composition of the present disclosure.
  • the compositions are applied locally.
  • the compositions are applied topically.
  • the compositions are applied mucosally, e.g., to a mucous membrane. Administration can be accomplished to organs, cells, tissue cultures, or to living organisms, for example a human.
  • a “therapeutic” treatment is the administration of a composition of the present disclosure to a subject experiencing or exhibiting signs or symptoms of the diseases or disorders disclosed herein for the purpose of diminishing or eliminating those diseases, disorders and/or their symptoms.
  • the subject is mammalian.
  • the subject is human.
  • the subject is a primate, which in one embodiment, is a non-human primate.
  • the subject is murine, which in one embodiment is a mouse, and, in another embodiment is a rat.
  • the subject is canine, feline, bovine, equine, caprine, ovine, porcine, simian, ursine, vulpine, or lupine.
  • the subject is a chicken or a fish.
  • the composition of the present invention comprises a therapeutically effective amount of one or more of the compounds disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
  • a “therapeutically effective amount” of a composition of the present disclosure is an amount of the composition that is sufficient to provide a beneficial effect to the subject to which the composition is administered.
  • the pharmaceutical composition is administered locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material.
  • administration can be by direct injection, e.g, via a syringe, at the site of a tumor or neoplastic or pre-neoplastic tissue.
  • compositions of the present disclosure may be administered in combination with a biodegradable, biocompatible polymeric implant, which releases the compound over a controlled period of time at a selected site.
  • a biodegradable, biocompatible polymeric implant which releases the compound over a controlled period of time at a selected site.
  • polymeric materials include polyanhydrides, polyorthoesters, polyglycolic acid, polylactic acid, polyethylene vinyl acetate, copolymers and blends thereof (See, e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla.).
  • a controlled release system may be placed in proximity of the site to be administered.
  • compositions of the present disclosure may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other therapeutically active agents.
  • infusion or bolus injection by absorption through epithelial linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other therapeutically active agents.
  • epithelial linings e.g., oral mucosa, rectal and intestinal mucosa, etc.
  • compositions and formulations disclosed herein may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject provides or evidences an indication of treatment for example the alleviation of symptoms related to the disorder).
  • Effective doses will vary depending on the route of administration, in addition to the usage with other pharmaceutical and/or medicinal agents.
  • amelioration means a lessening of severity of at least one indicator of a condition or disease.
  • amelioration includes a delay or slowing in the progression of one or more indicators of a condition or disease. The severity of indicators may be determined by subjective or objective measures which are known to those skilled in the art.
  • compositions of the present disclosure that will be effective for a particular fibrotic disease or disorder will depend on the nature of the disease or disorder, and may be determined using clinical techniques known to those of skill in the art.
  • in vitro assays may optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may also be extrapolated from dose-response curves derived from in vitro or animal model bioassays or systems.
  • the composition of the present disclosure is administered once per day. In another embodiment, the composition of the present disclosure is administered twice per day. In another embodiment, the composition of the present disclosure is administered three times per day. In another embodiment, the composition of the present disclosure is administered four times per day. In another embodiment, the composition of the present disclosure is administered hourly. In another embodiment, the composition of the present disclosure is administered once every two days, once every three days, twice a week, once a week, once every 2 weeks, once every 3 weeks.
  • the composition of the present disclosure is administered for 7 days to 28 days. In another embodiment, the composition of the present disclosure is administered for 7 days to 8 weeks. In another embodiment, the composition of the present disclosure is administered for 7 days to 50 days. In another embodiment, the composition of the present disclosure is administered for 7 days to six months. In another embodiment, the composition of the present disclosure is administered for 7 days to one and half years. In another embodiment, the composition of the present disclosure is administered for 14 days to 12 months. In another embodiment, the composition of the present disclosure is administered for 14 days to 3 years. In another embodiment, the composition of the present disclosure is administered for several years. In another embodiment, the composition of the present disclosure is administered for one month to six months. In another embodiment, the composition of the present disclosure is administered until the subject no longer experiences or exhibits symptoms of the fibrotic disease or disorder.
  • Another embodiment is a kit for the treatment of the fibrotic diseases and disorders of the present disclosure.
  • Dupuytren’s Disease of the hands is an early form of what most likely will evolve overtime into Dupuytren’s Contracture of the hands. This relatively infrequent disease is based on northern European ancestry that increases in incidence typically from age 45-50 years of age with increasing incidence and severity of existing disease throughout the rest of these people's lives. There is a mild increase in the incidence of males over females in the progression of the disease. The earlier in life it begins the expectation of more accelerated progression, and the involvement of more fingers will be experienced. It converts from Dupuytren’s Disease to Dupuytren's Contracture when the fingers begin to bend in towards the palms.
  • the abnormality begins as the Disease with the discovery of a subcutaneous nodule on the palmar surface of the hand that is usually not tender at the base of fingers 3, 4, and 5 on either hand. After a relatively short time, abnormal skin folds begin to develop below the nodule into the palm. Additional nodules may form then or at any time in the future on either hand mostly involving fingers 3, 4, and 5. Another example of involvement of any finger is observed by placing the palm on a flat surface and determining the ability to raise the affected finger up off the table. Over time, the involved fingers will not be able to rise above the flat surface.
  • composition halts the progression of Dupuytren's disease to the
  • the first is a 73 year old male, 5 foot 6 inches weighing 139 pounds who had untreated contractures on the right hand for 11 years and on the left hand for 16 years.
  • the right hand Prior to treatment, the right hand had a fifth finger Stage 3 contracture with 100° of flexion and a left hand fifth finger Stage 4 contracture with 150° of flexion.
  • the right hand fifth finger contraction reduced to a Stage 2 contracture with 55° of flexion, but the left hand Stage 4 contraction treated for the same time remained a stage 4 lesion that only reduced to a 140° of flexion.
  • the second patient in this preliminary trial was also a 73 year old male, 5 foot 8 inches weighing 194 pounds who had untreated contractures on the right fifth digit Stage I with 25° of flexion and a fourth digit Stage 2 with 75° of flexion for 13 years.
  • the left hand had a fifth digit Stage 3 contraction with 95° of flexion and a fourth finger Stage 4 contraction with 140° contraction for 9 years.
  • the right hand fith digit Stage 1 lesion with 25° of flexion remained a Stage 1 but no longer had any degrees of flexion.
  • the right hand fourth digit Stage 2 contracture with 75° flexion reduced to 55° of flexion.
  • Cocoa butter contains Oleic acid (34.5% - Omega-9, used in food and soap), Stearic acid (34.5% - surfactant, detergents, soaps, lubricants), Palmitic acid (26.0% - soaps, food compositions, cosmetics), Linoleic acid (3.2% - Omega-6, essential oil, surfactant, anti-inflammatory), Arachidic acid (1.0% - detergents, lubricants) and Palmitoleic acid (0.3% - Omega-7).
  • Cottonseed oil is a cooking oil. Sodium pyruvate protects against peroxides. Tocopherol acetate is a form of Vitamin E that can resist acid destruction. None of these NEOSPORINTM components are able to hasten healing in the skin.
  • a 39 year white male was a bicycle rider going on trails in the area. He fell while riding a trail and landed on his left side inducing a large, 5 by 12 cm skin abrasion with bleeding. On return from the ride, he washed it off and placed NEOSPORINTM on the wound. The next day, he was offered to replace the NEOSPORINTM with the disclosed composition. His experience with NEOSPORINTM for this kind of partial thickness skin wound, would take 10 to 14 days for it to heal. The three times a day usage of this product permitted the healing to be essentially over in 5-6 days with little evidence of scarring.
  • the disclosed composition was applied to the injury after cleaning.
  • the disclosed composition was applied three times a day. By the second day, the wound was closed and no longer weeping fluid and had lost most of its pain. By the fourth day, the wound was essentially healed over and without pain or sign of infection.
  • the disclosed composition treats injuries without infection, and healed in half the time usually required for NEOSPORINTM.
  • Table 6 lists the composition formulation for treatment of cuts, abrasions, and minor burns.
  • Peyronie’s Disease is a connective tissue disorder of the penis affecting 5% of the male population. It involves fibrous plaques developing along the fibrous sheath, the tunica albuginea, that surrounds the spongy erectile tissue, the corpus cavernosa, in the penis. When the penis fills with blood and erects, these fibrous plaques or bands prevent that portion of the penis from erecting properly. This leads to two types of deformities of the penis: the more common is a marked curvature of the penis in any direction at the point of the stricture ( Figure 3) while the least common is an hour glass stricture completely around the penis.
  • Table 7 lists the composition formulation for treatment of Peyronie’s Disease or Induration Penis Plastica.
  • test subject was allowed to apply the disclosed composition to both forearms after the changes became quite obvious when examining both forearms.
  • Several months of continued use of the disclosed composition on both forearms shows established hair, both dark and white, growing well to its normal length, increased dermal thickening, strengthening and thickening of the epidermis without any new tears, and ongoing reduction in the actinic keratoses size and appearance.
  • Table 8 lists the composition formulation for treatment of exposed aging skin.
  • Toe nail fungus is medically known as onychomycosis, or tinea unguium, commonly affects toe nails and can be progressive to the state of nail destruction, if not treated properly (Figure 5). It can also affect the finger nails. It is the most common of all the nail afflictions affecting 10% of the population and represents 50% of all nail afflictions. The progression is from mild forms to the most severe with loss of most of the normal nail.
  • the pathogens involved in onchyomycosis are all represented in the fungus kingdom that includes dermatophytes in the western world and Candida and non- dermatophyes in the tropics and subtropics.
  • the dermatophytes most common representative is Trichophyton rubrum with multiple related species.
  • Candida species predominantly affect the finger nails, rather than the toe nails.
  • the non-dermatophytes are predominantly molds, mostly from the genus of Neoscytalidium, Scopulariopsis, and Aspergillus.
  • Conditions that can be confused with onychomycosis include nail psoriasis, lichen planus, contact dermatitis, and nail bed tumors such as melanoma, thrauma, and Q yellow nail syndrome.
  • Table 9 lists the composition formulation for treatment of toe nail fungus.
  • Aphthous ulcers or stomatitis are characterized by repeated, benign and non- contagious oral cavity ulcerations that are self-limited to usually 7-10 days, as shown in Figure 6. These are painful and sensitive to increased pain by topical exposure to compositions with excessive pH, spices, and increased temperature. Episodes usually occur 3-6 times a year for several years around the time of adolescence. There is no known cause but are thought to be multi-factorial.
  • ulceration triggers While the ulceration triggers are not identified, the ulcers develop due to immune cell reactions from T-cells, mast cells, and macrophages to unknown triggers with the emphasis on T- cell involvement. Forty percent of persons getting these lesions have a family history of involvement. Some episodes seem to clearly be responding to acute, excessive stress in those who get these ulcers, but most do not. The natural duration of 7-10 days remains fairly uniform, even in spite of several different types of proposed treatments.
  • the disclosed composition has demonstrated the ability to reduce the duration of these ulcers to 2-4 days while relieving the pain. However, it does not appear to prevent the regular occurrence of these ulcers. Approximately 10 patients have used this formulation and uniformly experience a shorter duration of time and a reduction of pain.
  • a 65 year old white male was having occasional episodes of aphthous ulcers of the mouth that were typical in severity and duration with pain lasting 7 to IO days and final clearing from 2 to 2.5 weeks. These aphthous ulcers were occurring every three to four months without an obvious cause.
  • the disclosed composition was applied at the start of an episode.
  • the disclosed composition was designed to be thick enough to stay within the bed of the ulcer with application 2 to 4 times a day. From starting the use of the disclosed composition on the first day of the lesion appearing, and treating it 3 times a day after meals and again at bed time, the ulcer lost its pain in 2-3 days and disappeared in 4-5 days. Due to benzocaine being used as a product ingredient, the ulcer had a significant decrease in pain during the treatment phase and prior to its healing.
  • Table 10 lists the composition formulation for treatment of aphthous ulcers of the mouth.
  • Scleroderma is a systemic disease that results in progressive fibrosis of organs starting with skin lesions that can then progress to involving major organs, such as, the heart, lungs, intestines and kidneys.
  • the pathophysiology for the skin appears to involve the laying down in a random orientation of collagen much like scar formation diffusively in the subcutaneous tissues. This leads to joint immobilization starting in the fingers and spreading into the wrists and elbows as well as in the toes and ankle (Figure 7). Its increased pressure beneath the skin also reduces blood flow causing extensive Raynaud's phenomenon, or skin blanching episodes on the digits that readily leads to poorly healing ulcerations and potential digit loss.
  • Table 11 lists the composition formulation for treatment of cutaneous scleroderma.
  • Raynaud's Phenomenon or Syndrome is a medical condition that involves episodic spasm of the arteries that markedly reduces blood flow to the hands and/or feet that can eventually lead to poorly healing ulcers and to gangrene with loss of digits (Figure 8). The episodes affecting
  • the hands or feet initially turn white and later blue, often with associated numbness or pain. As the spasm ends with blood flow returning, the affected parts turn red and are typically painful. These episodes usually only last a few minutes, but can last for hours.
  • the secondary conditions that can cause these episodes include immune disorders, such as, lupus and scleroderma, former trauma including frost bite, smoking, thyroid problems, and certain medications, such as, birth control pills.
  • the existing primary treatment is to eliminate known stimulants, such as, smoking and to avoid exposing the affected extremities to cold temperatures. If these are not effective, then calcium channel blockers or a vasodilator can be tried. There currently are no other known remedies.
  • Table 12 lists the composition formulation for treatment of Raynaud' s Phenomenon.
  • Table 13 lists the composition formulation for treatment of chemotherapy / radiation therapy induced oral mucosa! lesions.
  • the methods involved in producing these compositions are generally similar but have different components for each composition.
  • the first temperature level forthefirst mixture is set at 40°C to 50°C, preferably 45°C, with a 300 to 500 rotations per minute (RPM), preferably 400 RPM, propeller mixing speed. All of the components that are a liquid or become a liquid at that temperature are mixed together in one of two vessels: a hydrophobic vessel and a hydrophilic vessel. The remaining unmixed components require highertemperatures to become liquid.
  • the temperatures ofthe mixtures are increased to 60°C to 80°C, preferably 60°C, and the speed of rotation is increased to 700 to 900 RPM, preferably 800 RPM.
  • the remaining hydrophobic group components are added to its vessel and the hydrophilic group components are added to its vessel.
  • the mixed hydrophilic group of components is then poured into the hydrophobic group vessel, maintaining the 700 to 900 RPM, preferably 800 RPM and the 60°C to 80°C, preferably 60°C, temperature for another 10- 40 minutes, preferably 20 minutes, of reach on time.
  • the mixture is slowly cooled to room temperature over several hours of 2 to 10 hours while reducing the mixing speed to 500- 700 RPM, preferably 600 RPM, continuing to insulate the mixing container.
  • This lets the mixture cool to ambient room temperature of 25°C to 37°C, preferably 25°C, over a slow period time while continuously being thoroughly mixed.
  • the propeller is stopped and this final mixing vessel is removed to a surface top.
  • This final composition will remain semisolid until it is returned to partial liquid at 37°C by design to melt onto the skin when applied.
  • Filling individual pumps (15 ml to 50 ml) is the final step prior to storage and then for delivery of this composition to the purchaser on a regular basis.
  • hDFa Primary human adult dermal fibroblast
  • Dermal myofibroblast (hDMFa) cell were obtained through differentiation of hDFa cells by plating the hDFa cells at low density (approx. 500 cell per cm 2 ) and growing until confluent.
  • the cell proliferation assay MTS reagent sulfonyl-tetrazolium salt was obtained from Abeam pic, Product No. ab223881, CAS No. 138169-43-4. The assay was performed as described by the manufacturer.
  • hDMFa myofibroblast cells were cultured in a 96-well plate containing 200 pL of media and grown to approximately 80-90% confluence. The growth serum was removed and replaced with 200 pL of fresh serum-free media containing varying concentrations of inhibitor. The cells were then incubated for an additional 8-12 hours in the inhibitor media. Post incubation cell viability was measured by adding MTS reagent to each well (10-20 pL), including treated and untreated negative control wells. Absorbance of the resulting formazan (formed in viable cells only) was measured using a 96-well plate reader after 3-6 hours of incubation at 37°C. Inhibition data for each well was normalized as a percentage of the negative control and are reported in the tables below. Results ranged from low (+) to high (+++++) inhibitory activity. Table 14

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions topiques et des procédés pour le traitement et/ou l'amélioration de maladies, de troubles fibrotiques dermiques et transdermiques, de la douleur et de l'inflammation associées, y compris la maladie de Dupuytren, la contracture de Dupuytren, la maladie de Ledderhose, la maladie de La Peyronie, la sclérodermie, et le phénomène de Raynaud (ou Renaud's), la cicatrisation des plaies, telles que l'endommagement de la peau par coupures, abrasions et brûlures, ainsi que les changements cutanés dus au vieillissement, les mycoses des ongles d'orteils et l'ulcération de la muqueuse buccale et les ulcères aphteux induits par la chimiothérapie et/ou la radiothérapie. L'invention concerne également des procédés de fabrication desdites compositions topiques.
PCT/US2023/034056 2022-09-28 2023-09-28 Compositions topiques et procédés pour le traitement de maladies fibrotiques dermiques et transdermiques, de troubles et de la douleur et de l'inflammation associées WO2024073011A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411048P 2022-09-28 2022-09-28
US63/411,048 2022-09-28

Publications (1)

Publication Number Publication Date
WO2024073011A1 true WO2024073011A1 (fr) 2024-04-04

Family

ID=90479028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/034056 WO2024073011A1 (fr) 2022-09-28 2023-09-28 Compositions topiques et procédés pour le traitement de maladies fibrotiques dermiques et transdermiques, de troubles et de la douleur et de l'inflammation associées

Country Status (1)

Country Link
WO (1) WO2024073011A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151232A1 (en) * 2017-11-22 2019-05-23 Progeneron Topical Compositions, Process of Manufacture and Method of Use
WO2021236108A1 (fr) * 2020-05-22 2021-11-25 Progeneron, Llc Compositions topiques, procédé de fabrication à grande échelle et méthode d'utilisation
WO2022024095A2 (fr) * 2020-07-31 2022-02-03 Ai Pharmaceuticals Jamaica Limited Compositions et procédés pour le traitement d'une inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151232A1 (en) * 2017-11-22 2019-05-23 Progeneron Topical Compositions, Process of Manufacture and Method of Use
WO2021236108A1 (fr) * 2020-05-22 2021-11-25 Progeneron, Llc Compositions topiques, procédé de fabrication à grande échelle et méthode d'utilisation
WO2022024095A2 (fr) * 2020-07-31 2022-02-03 Ai Pharmaceuticals Jamaica Limited Compositions et procédés pour le traitement d'une inflammation

Similar Documents

Publication Publication Date Title
AU2008266971B2 (en) Topical composition for treating pain
US20200179305A1 (en) Compositions for the Treatment of Hyperkeratosis Disorders
JP6121561B2 (ja) 組織再生のための組成物および方法
US20190151232A1 (en) Topical Compositions, Process of Manufacture and Method of Use
US11564963B2 (en) Topical compositions, process of large-scale manufacture, and method of use
HU211689A9 (en) Treatment of disease employing hyaluronic acid and nsaids
CN108135965B (zh) 用于伤口愈合的含p物质的药物组合物
US20230165825A1 (en) Novel anhydrous compositions comprised of marine oils
RU2580622C2 (ru) Композиция и ее применение в лечении анальных трещин
US10426803B2 (en) Topical medicament for skin and mucosal injuries
US11696907B2 (en) Wound healing composition
US6406706B1 (en) Use of α- and β-santalols major constituents of sandal wood oil, in the treatment of warts, skin blemishes and other viral-induced tumors
WO2021236108A1 (fr) Compositions topiques, procédé de fabrication à grande échelle et méthode d'utilisation
WO2024073011A1 (fr) Compositions topiques et procédés pour le traitement de maladies fibrotiques dermiques et transdermiques, de troubles et de la douleur et de l'inflammation associées
WO2024073013A1 (fr) Traitement combiné de maladies fibrotiques dermiques et transdermiques, de troubles, et de la douleur et de l'inflammation associées
TW201642846A (zh) 用於拉伸紋局部處理之羧甲基半胱胺酸
KR20240101480A (ko) 카르니틴살리실레이트(ca-sa)를 유효성분으로 포함하는 피부 개선용 조성물
KR20240104289A (ko) 통증 완화용 조성물 및 이를 이용하여 통증을 완화하는 방법
EINSTEIN Dermatologic Pathologies
CN117279623A (zh) 伤口治疗组合物
Edwards Cyclopaedia of the Diseases of Children, Medical and Surgical
Conrad et al. AMERICAN ACADEMY OF DERMATOLOGY AND SYPHILOLOGY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23873640

Country of ref document: EP

Kind code of ref document: A1